Skip to content
SHOP
  • Home
  • About
  • Science
  • Pipeline
  • News
  • Contact
  • Home
  • About
  • Science
  • Pipeline
  • News
  • Contact
SHOP

News

BioVinc Presentation in 2022 ORS Meeting

February 2, 2022

BioVinc Presentation in 2021 ICPC Meeting

July 10, 2021

BioVinc Presentation in 2020 ASBMR Meeting

September 10, 2020

BioVinc Awarded SBIR Phase II Grant by NIH/NIAID to Advance Novel Treatment for Prosthetic Joint Infections

January 15, 2020

BioVinc Presentations in Bisphosphonates 2019 Meeting: Celebrating 50 Years

December 7, 2019

Holiday Discounts

December 1, 2019

Biovinc Presentations in 2019 ABSMR Meeting

September 18, 2019

Biovinc Presentations in 2018 ASBMR Meeting

September 20, 2018

BioVinc Collaborator Presentation at the 2018 AADR Annual Meeting

March 1, 2018
Previous Page1 Page2 Page3 Next

BioVinc (BV) has pioneered a groundbreaking skeletal-targeted therapy for life-threatening orthopedic infections and osteomyelitis. This innovation makes it possible to eradicate biofilms, including the previously untreatable MRSA on infected implants—offering new hope to prevent amputation and save lives.

Linkedin-in Youtube

BioVinc Data Room

We welcome investors to review our recent OsteoFloxacin™ data and trial results.

Request Access

LINKS

  • About Us
  • Our Science
  • Pipeline
  • News

CONTACT US

2265 E. Foothill Blvd.
Pasadena, CA 91107 USA

+1 (310) 730-5609

info@biovinc.com

©2026 BioVinc, LLC. All rights reserved.
  • Privacy Policy
  • Terms & Conditions
Biotech Website Design
stellar biotech design